Adaptimmune Therapeutics PLC · OTC:ADAPY

Adaptimmune Therapeutics — Investor Presentation (November 2015)

34 slides from Adaptimmune Therapeutics's investor presentation, Nov 18, 2015

  1. Slide 1: Disclaimer

    Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o

  2. Slide 2: Investment Highlights

    Investment Highlights Focused on affinity enhanced T-cell therapies for autologous T-cell therapeutics to treat cancer Lead clinical candidate targeting NY-ESO : SITC 2015 data Synovial sarcoma – In patients receiving target dose of 1x109 cells: 60% RR; 90% remain alive and on long-term follow up Mu

  3. Slide 3: TCR Platform built up over 16 years

    TCR Platform built up over 16 years 1999-2006 Avidex formed on basis of TCR technology from Oxford University Acquired by Medigene (2006) 2008 Adaptimmune formed as a virtual company with UPenn collaboration 2011-2014 Adaptimmune establishes R&D infrastructure and delivers promising clinical data 20

  4. Slide 4: Experienced Management Team and Board

    Experienced Management Team and Board Executive Management Name: Title: Experience: James Noble, MA, FCA CEO & Co-Founder Helen Tayton-Martin, PhD MBA COO & Co-Founder Adrian Rawcliffe CFO Rafael Amado, MD CMO Gwen Binder-Scholl, PhD EVP, Adaptimmune LLC Board of Directors Name: Affiliation: Experie

  5. Slide 5: TCRs recognize intracellular cancer antigens

    TCRs recognize intracellular cancer antigens The TCR is the natural mechanism for T-cells to distinguish a diseased cell from a healthy cell All proteins, including intracellular ones, are processed and presented as HLA-peptide complexes which are recognized by TCRs Many cancer targets are intracell

  6. Slide 6: ADAP Pipeline: Next Steps with NY-ESO

    Indication Research Pre-IND Phase 1/2 GSK option to license ADAP Pipeline: Next Steps with NY-ESO Cohort 1: High NY-ESO expression, 12 patients Esophageal Synovial Sarcoma Cohort 2: Low NY-ESO expression, 10 patients Cohort 3: Removal of fludarabine, 10 patients Cohort 1: Autologous SCT, 25 patients

  7. Slide 7: ADAP Pipeline: Next Steps

    MAGE-A10 TCR Indication Research Pre-IND Phase 1/2 ADAP Pipeline: Next Steps Wholly-owned ADAP Targets IND open Non-small cell lung cancer (NSCLC) Basket study: Solid tumors NIH RAC approval received Hepatocellular cancer Synovial Sarcoma 12 undisclosed cancer targets AFP TCR Research programs Adapt

  8. Slide 8: Platform and Differentiation

    Platform and Differentiation

  9. Slide 9: Finding the Right Targets

    Finding the Right Targets Tumour cell Only low risk targets selected for TCR programs Over thirty validated targets and growing Engineered TCRs Safety Testing Robust Manufacturing Validated Targets Mass spectrometry Confirms surface expression and expression on tumor cells (i.e. not normal tissue) I

  10. Slide 10: Finding the Right TCR Affinity

    Finding the Right TCR Affinity Safety Testing Robust Manufacturing Validated Targets Engineered TCRs Proprietary ability to make optimum engineered TCRs 1mM 100mM 10mM 1mM Individual TCRs in test panel Natural T cell Response – natural affinity TCR Adaptimmune engineered TCR T cell response Increasi

  11. Slide 11: Proprietary Safety Testing

    3D primary cultures and iCells Normal Primary Cell Screen Molecular Analysis Human Cell Testing Whole Blood Assay Allo-reactivity Screen “Core motif” identification Core motif genome search X-scan peptide mapping Redefined completely following two deaths on MAGE A3 study in 2011/12* *Linette et al,

  12. Slide 12: Proprietary Process for Manufacturing

    Proprietary Process for Manufacturing Leukapheresis Prepare patient with lymphodepletion Collection Infusion Natural T-cells isolated from patients Genes encoding enhanced TCR delivered to patient’s natural T-cells Lentiviral vector Enhanced T-cells expanded Exclusive license to DynaBeads® CD3/CD28

  13. Slide 13: Proprietary Process for Manufacturing

    Proprietary Process for Manufacturing Validated Targets | sp | Engineered TCRs | > | Safety Testing J» | Robust Manufacturing Leukapheresis Natural T-cells isolated from patients Genes encoding Engineered TCR enhanced TCR — delivered to patient's © lentiviral OOO: natural T-cells vector Vein to vein

  14. Slide 14: ADAP Phase I/II Study in Synovial Sarcoma

    ADAP Phase I/II Study in Synovial Sarcoma Generally incurable; 75% to 80% of patients do not survive past two to three years First line therapy: radiotherapy and chemotherapy, surgical resection where possible Study Design: Multicenter pilot study in 12 patients, objectives: Determine the response r

  15. Slide 15: Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence

    Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence 60% response rate in the 10 patients who received target cell dose (at least 1x109 NY-ESO-1C259T cells) 50% overall response rate (6/12) in patients receiving any dose of cells 75% (9/12) of all patients - and 90% (9/10) of pat

  16. Slide 16: Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence

    Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence Generally well tolerated; indicative of a favorable risk:benefit profile The majority of adverse events occur within the first 2 weeks following cell infusion and resolve within 30 days. Evidence of pseudo-progression and gradu

  17. Slide 17: Radiographic Pseudoprogression and Response of Lung Metastases

    ADAP Phase I/II Study in Synovial Sarcoma Radiographic Pseudoprogression and Response of Lung Metastases Baseline: Bilateral Miliary Metastatic disease Day +2: Pseudoprogression due to Immune Infilration Day +101: Complete Response Patient 201 NY-ESO C-Reactive Protein AACR April 2015

  18. Slide 18: Partial Response Followed by Tumor Resection in Sarcoma

    NY-ESO TCR T cells administered ADAP Phase I/II Study in Synovial Sarcoma Partial Response Followed by Tumor Resection in Sarcoma One month post NY-ESO TCR T cells Two months post NY-ESO T cells Source: Merchant, CTOS, 2014 ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-

  19. Slide 19: NY-ESO TCR T cells administered

    NY-ESO TCR T ‘One month ‘Two months cells post NY-ESO post NY-ESOT administered TCR T cells cells * ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-cells * The lesion was then deemed capable of resection

  20. Slide 20: ADAP Phase I/II Study in Multiple Myeloma

    ADAP Phase I/II Study in Multiple Myeloma Study Design US prevalence: 77,600 cases - approximately 27,000 new cases expected in 2015 Average five-year survival rates are estimated to be less than 45 percent Study Design: All enrolled patients (n=25) had symptomatic myeloma with active disease High r

  21. Slide 21: Multiple Myeloma Compelling Response Rate Compared to Published Literature

    ADAP Phase I/II Study in Multiple Myeloma Compelling Response Rate Compared to Published Literature Two year overall survival (OS) and progression free survival (PFS) as of November 2015 16/25 patients remain alive; 8/25 remain in remission Median PFS = 19.1 months Median OS = 32.1 months Response r

  22. Slide 22: Multiple Myeloma Encouraging Tolerability and Persistence

    ADAP Phase I/II Study in Multiple Myeloma Encouraging Tolerability and Persistence Generally well tolerated; indicative of a favorable risk:benefit profile All SAEs possibly related to the NY-ESO T-cells resolved No clinically apparent cytokine release syndrome despite high IL-6 levels CAR-Ts have b

  23. Slide 23: ADAP Pipeline: Next Steps with NY-ESO

    Indication Research Pre-IND Phase 1/2 GSK option to license ADAP Pipeline: Next Steps with NY-ESO Cohort 1: High NY-ESO expression, 12 patients Esophageal Synovial Sarcoma Cohort 2: Low NY-ESO expression, 10 patients Cohort 3: Removal of fludarabine, 10 patients Cohort 1: Autologous SCT, 25 patients

  24. Slide 24: MAGE-A10 Proprietary target

    MAGE-A10 Proprietary target

  25. Slide 25: MAGE A10 expression from cancer genome atlas

    MAGE A10 expression from cancer genome atlas (TCGA) breast bladder lung head & neck melanoma ovarian MAGE-A10 – A multi-cancer target testis RNAseq (Log scale) GTEx Portal MAGE A10 expression is absent/low in most adult non-reproductive tissue tissues

  26. Slide 26: IND for MAGE A-10 TCR therapeutic filed

    IND for MAGE A-10 TCR therapeutic filed Preclinical testing complete NIH RAC approval obtained: March 10, 2015 IND approved: announced July 2, 2015 Initial trial in NSCLC expected to open in 2015 Basket study anticipated in 2016 in multiple cancers potentially including bladder, head and neck, breas

  27. Slide 27: ADAP Pipeline: Next Steps

    MAGE-A10 TCR Indication Research Pre-IND Phase 1/2 ADAP Pipeline: Next Steps Wholly-owned ADAP Targets IND open Non-small cell lung cancer (NSCLC) Basket study: Solid tumors NIH RAC approval received Hepatocellular cancer Synovial Sarcoma 12 undisclosed cancer targets AFP TCR Research programs Adapt

  28. Slide 28: ADAP Pipeline: Next Steps

    ADAP Pipeline: Next Steps Wholly-owned ADAP Targets [Xe SU Rie Non-smail cell lung cancer IND open Enrollment shortly Basket study: Solid tumors > Enrollment in 2016 Generation 2 ; IND 2017 PGR e MM Hepatocellular cancer NIH RAC approval received IND planned 1H 2016 research programs Research & =n t

  29. Slide 29: The GSK Strategic Collaboration

    The GSK Strategic Collaboration Announced June 2014: Up-front payment £25 million GSK has option to license NY-ESO at end of Phase 1/2 studies Adaptimmune conducts all clinical and non-clinical development work Enables Adaptimmune to optimize regulatory, vector, cell processing, analytical, automati

  30. Slide 30: Large un-partnered pipeline with ability to target almost all major tumors

    Large un-partnered pipeline with ability to target almost all major tumors Adaptimmune GSK 20+ Additional validated targets Twelve new targets selected for development Not yet nominated; programs with work ongoing are excluded Pool of 3: ADAP keeps 2 NY-ESO MAGE-A10 AFP 30+ validated therapeutic tar

  31. Slide 31: Key 2015/2016 Milestones YTD and Anticipated

    Key 2015/2016 Milestones YTD and Anticipated Q1 2015 Additions to Adaptimmune senior leadership team April 2015 AACR presented full cohort data for NY-ESO in Sarcoma and MM May 2015 IPO raises $176m net proceeds Q2 2015 Filing and acceptance of IND for Phase 1/2 studies for MAGE A-10 Q3 2015 Publica

  32. Slide 32: Investment Highlights

    Investment Highlights Focused on affinity enhanced T-cell therapies for autologous T-cell therapeutics to treat cancer Lead clinical candidate targeting NY-ESO : SITC 2015 data Synovial sarcoma – In patients receiving target dose of 1x109 cells: 60% RR; 90% remain alive and on long-term follow up Mu

  33. Slide 33: Adaptimmune Engineered TCR T cell therapy Presentation Materials November 2015

    Adaptimmune Engineered TCR T cell therapy Presentation Materials November 2015

  34. Slide 34: Adaptimmune

    Adaptimmune Engineered TCR T cell therapy Presentation Materials November 2015 }€ Adaptimmune

Adaptimmune Therapeutics — Investor Presentation (November 2015) on 6ix